Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04119050 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
A Phase 2 study of Warm Autoimmune Hemolytic Anemia, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 20
- Study locations
NCT04119050: Active Phase 2 study of Warm Autoimmune Hemolytic Anemia, sponsored by Janssen Research & Development.
NCT04119050 is a Phase 2 study of Warm Autoimmune Hemolytic Anemia that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 118 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04119050, a Phase 2 study of Warm Autoimmune Hemolytic Anemia, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG M281
Study Locations (20)
Florida
- GNP Research - Cooper City
- University of Florida College of Medicine - Gainesville
- 21st Century Oncology - Jacksonville
- Lakes Research - Miami Lakes
- AdventHealth Cancer Institute - Orlando
- Children's Research Institute - St. Petersburg
California
- MemorialCare Medical Group - Fountain Valley
- University of Southern California - Los Angeles
- Compassionate Cancer Care - Riverside
- American Institute of Research - Whittier
New York
- Montefiore Medical Center - Lake Success
- Monter Cancer Center - Lake Success
- Hematology Oncology Associates of Rockland - Nyack
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Illinois
- Rush University Medical Center - Chicago
Kansas
- Alliance for Multispeciality Research - Merriam
Louisiana
- Tulane University School of Medicine - New Orleans
Michigan
- Henry Ford Medical Center - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2019-08-15 |
| Est. Completion | 2028-04-01 |
| Phase | Phase 2 |
What the registry record for NCT04119050 still lists
NCT04119050 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower).
The record links to 1 condition, with Warm Autoimmune Hemolytic Anemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04119050 names 20 study sites across 10 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT04119050 about?
NCT04119050 is a clinical study titled "Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia". The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).
What is the current status of trial NCT04119050?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2019-08-15. Estimated completion is 2028-04-01.
What conditions does trial NCT04119050 study?
This clinical trial studies the following conditions: Warm Autoimmune Hemolytic Anemia.
What interventions are being tested in trial NCT04119050?
The interventions under investigation include: Placebo (DRUG), M281 (DRUG).
Who is sponsoring clinical trial NCT04119050?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04119050 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Warm Autoimmune Hemolytic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04119050's enrollment target sits among peer trials
118 618th of 2000 higher than 1,378 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI